Search
Prestige Consumer Healthcare Inc
PBHAdd to Watchlist
50.160USD
-1.220-2.37%
Close 08-17 16:00（ET）Quotes delayed by 15 min
2.37BMarket Cap
12.77P/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Prestige Consumer Healthcare Inc is 8.00, ranking 59 out of 156 in the Pharmaceuticals industry. The average price target is 76.00, with a high of 88.00 and a low of 70.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
67.250
Target Price
+30.89%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Prestige Consumer Healthcare Inc
PBH
6
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Prestige Consumer Healthcare Inc's expected revenue for the next quarter?
Prestige Consumer Healthcare Inc's expected revenue is 329.17M.
What is Prestige Consumer Healthcare Inc's price target?
Analysts forecast that Prestige Consumer Healthcare Inc's price target is USD 76.00, with the highest forecast at USD 88.00 and the lowest forecast at USD 70.00.
How have Prestige Consumer Healthcare IncPBH's recent earnings per share performed?
The market expectation was USD 0.61, while Prestige Consumer Healthcare IncPBH's earnings per share (EPS) for the previous quarter was USD 1.14. EPS for the next quarter is expected at USD 1.07.
What is the analyst rating for Prestige Consumer Healthcare Inc?
Based on the ratings of Prestige Consumer Healthcare Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.